MedTrace Logo

Study of Single IV Administration of P2G12

NCT02923999 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-01-18

No results posted yet for this study

Summary

A randomised phase I trial of a monoclonal antibody which neutralises HIV-1 (P2G12) to be given as a single intravenous infusion to healthy human volunteers to assess the safety and reactogenicity

Conditions

  • HIV Infection

Interventions

DRUG

P2G12 Dose Cohort 1

single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody

DRUG

P2G12 Dose Cohort 2

single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody

DRUG

P2G12 Dose Cohort 3

single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody

Sponsors & Collaborators

  • St George's, University of London

    lead OTHER

Principal Investigators

  • Catherine Cosgrove · St George's, University of London

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-31
Primary Completion
2020-08-31
Completion
2020-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02923999 on ClinicalTrials.gov